AstraZeneca Investor Day Presentation Deck

Secondary Endpoint: PFS by investigator assessment Progression-Free Survival probability,% 13 100 80 60 40 20 0 Patients Still at Risk: 0 + 1 Censor T-DXd (n = 261) T-DM1 (n = 263) 2 3 4 5 6 7 8 9 T-DXd (261) 261 256 250 244 240 224 214 202 T-DM1 (263) 263 252 200 163 155 132 108 96 200 183 93 78 10 11 12 13 168 164 65 60 150 132 51 43 15 16 17 18 Time, months 14 112 105 79 37 34 29 64 53 23 21 19 45 16 mPFS, mo (95% CI) 12-mo PFS rate, % (95% CI) HR (95% CI) 20 36 12 +HI 21 29 8 22 25 6 23 19 4 24 10 1 T-DXd 25.1 (22.1-NE) 76.3 (70.4-81.2) 25 6 1 26 LO 5 1 0.26 (0.20-0.35) P= 6.5 X 10-24 27 3 1 T-DM1 7.2 (6.8-8.3) 34.9 (28.8-41.2) 28 29 2 1 0 1 30 0 1 31 32 00 1 0 B

View entire presentation